Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
• By Sten Stovall
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.
Celgene Corp. has made its first big foray into CNS by inking a strategic drug discovery and development collaboration with Germany's Evotec AG to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.
